For research use only. Not for therapeutic Use.
Salsalate is a nonsteroidal anti-inflammatory drug, a nonacetylated salicylate with no more problems of gastrointestinal bleeding than placebo. It inhibits synthesis and release of prostaglandins through the inactivation of cyclooxygenase-1 and COX-2. Salsalate is currently being investigated as a treatment for Type 2 diabetes with possible use to prevent the disease in people at risk. It reduces blood glucose concentrations in patients with type 2 diabetes, as well as in insulin-resistant patients without diabetes.
Catalog Number | A000715 |
CAS Number | 552-94-3 |
Synonyms | NSC-49171 |
Molecular Formula | C14H10O5 |
Purity | ≥95% |
Target | NF-κB |
Storage | -20°C |
InChI | InChI=1S/C14H10O5/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17/h1-8,15H,(H,16,17) |
InChIKey | WVYADZUPLLSGPU-UHFFFAOYSA-N |
SMILES | OC1=CC=CC=C1C(OC2=C(C(O)=O)C=CC=C2)=O |
Reference | </br>1: Liang W, Verschuren L, Mulder P, van der Hoorn JW, Verheij J, van Dam AD, Boon</br> MR, Princen HM, Havekes LM, Kleemann R, van den Hoek AM. Salsalate attenuates</br> diet induced non-alcoholic steatohepatitis in mice by decreasing lipogenic and</br> inflammatory processes. Br J Pharmacol. 2015 Nov;172(22):5293-305. doi:</br> 10.1111/bph.13315. Epub 2015 Oct 22. PubMed PMID: 26292849.</br>2: Rubin MR, Goldfine AB, McMahon DJ, Donovan DS, Cremers S, Dworakowski E,</br> Schaefer EJ, Shoelson SE, Silverberg SJ. Effects of the anti-inflammatory drug</br> salsalate on bone turnover in type 2 diabetes mellitus. Endocrine. 2015</br> Nov;50(2):504-7. doi: 10.1007/s12020-015-0535-8. Epub 2015 Feb 1. PubMed PMID:</br> 25636441; PubMed Central PMCID: PMC4522229.</br>3: Ariel D, Kim SH, Liu A, Abbasi F, Lamendola CA, Grove K, Tomasso V, Reaven GM.</br> Salsalate-induced changes in lipid, lipoprotein, and apoprotein concentrations in</br> overweight or obese, insulin-resistant, nondiabetic individuals. J Clin Lipidol. </br> 2015 Sep-Oct;9(5):658-63. doi: 10.1016/j.jacl.2015.06.009. Epub 2015 Jun 18.</br> PubMed PMID: 26350812; PubMed Central PMCID: PMC4594205.</br>4: Penesova A, Koska J, Ortega E, Bunt JC, Bogardus C, de Courten B. Salsalate</br> has no effect on insulin secretion but decreases insulin clearance: a randomized,</br> placebo-controlled trial in subjects without diabetes. Diabetes Obes Metab. 2015 </br> Jun;17(6):608-12. doi: 10.1111/dom.12450. Epub 2015 Mar 12. PubMed PMID:</br> 25683256.</br>5: van Dam AD, Nahon KJ, Kooijman S, van den Berg SM, Kanhai AA, Kikuchi T,</br> Heemskerk MM, van Harmelen V, Lombès M, van den Hoek AM, de Winther MP, Lutgens</br> E, Guigas B, Rensen PC, Boon MR. Salsalate activates brown adipose tissue in</br> mice. Diabetes. 2015 May;64(5):1544-54. doi: 10.2337/db14-1125. Epub 2014 Dec 4. </br> PubMed PMID: 25475439.</br>6: Alderete TL, Sattler FR, Richey JM, Allayee H, Mittelman SD, Sheng X, Tucci J,</br> Gyllenhammer LE, Grant EG, Goran MI. Salsalate treatment improves glycemia</br> without altering adipose tissue in nondiabetic obese hispanics. Obesity (Silver</br> Spring). 2015 Mar;23(3):543-51. doi: 10.1002/oby.20991. Epub 2015 Feb 3. PubMed</br> PMID: 25644856; PubMed Central PMCID: PMC4340767.</br>7: Kim SH, Liu A, Ariel D, Abbasi F, Lamendola C, Grove K, Tomasso V, Ochoa H,</br> Reaven G. Effect of salsalate on insulin action, secretion, and clearance in</br> nondiabetic, insulin-resistant individuals: a randomized, placebo-controlled</br> study. Diabetes Care. 2014 Jul;37(7):1944-50. doi: 10.2337/dc13-2977. PubMed</br> PMID: 24963111; PubMed Central PMCID: PMC4067392.</br>8: Goldfine AB, Jablonski KA, Shoelson SE, Creager MA; TINSAL-FMD (Targeting</br> Inflammation Using Salsalate in Type 2 Diabetes–Flow-Mediated Dilation) Ancillary</br> Study Team. Response to comment on Goldfine et al. Targeting inflammation using</br> salsalate in patients with type 2 diabetes: effects on flow-mediated dilation</br> (TINSAL-FMD). Diabetes care 2013;36:4132-4139. Diabetes Care. 2014</br> May;37(5):e112. doi: 10.2337/dc14-0222. PubMed PMID: 24757239.</br>9: Anderson K, Wherle L, Park M, Nelson K, Nguyen L. Salsalate, an old,</br> inexpensive drug with potential new indications: a review of the evidence from 3 </br> recent studies. Am Health Drug Benefits. 2014 Jun;7(4):231-5. Review. PubMed</br> PMID: 25126374; PubMed Central PMCID: PMC4105730.</br>10: Barzilay JI, Jablonski KA, Fonseca V, Shoelson SE, Goldfine AB, Strauch C,</br> Monnier VM; TINSAL-T2D Research Consortium. The impact of salsalate treatment on </br> serum levels of advanced glycation end products in type 2 diabetes. Diabetes</br> Care. 2014 Apr;37(4):1083-91. doi: 10.2337/dc13-1527. Epub 2013 Nov 19. PubMed</br> PMID: 24255104; PubMed Central PMCID: PMC3964486.</br>11: Pierce GL, Siefers K, Wegman-Points L. Comment on Goldfine et al. Targeting</br> inflammation using salsalate in patients with type 2 diabetes: effects on</br> flow-mediated dilation (TINSAL-FMD). Diabetes care 2013;36:4132-4139. Diabetes</br> Care. 2014 May;37(5):e110-1. doi: 10.2337/dc13-2781. PubMed PMID: 24757238.</br>12: Fakhri M, Imani EF, Khalili N. The effect of salsalate on biochemical factors</br> and endothelial dysfunction of prediabetic patients: A randomized clinical trial.</br> J Res Med Sci. 2014 Apr;19(4):287-92. PubMed PMID: 25097598; PubMed Central</br> PMCID: PMC4115341.</br>13: Wang X, DuBois DC, Cao Y, Jusko WJ, Almon RR. Diabetes disease progression in</br> Goto-Kakizaki rats: effects of salsalate treatment. Diabetes Metab Syndr Obes.</br> 2014 Aug 1;7:381-9. doi: 10.2147/DMSO.S65818. eCollection 2014. PubMed PMID:</br> 25120374; PubMed Central PMCID: PMC4128793.</br>14: Nohria A, Kinlay S, Buck JS, Redline W, Copeland-Halperin R, Kim S, Beckman</br> JA. The effect of salsalate therapy on endothelial function in a broad range of</br> subjects. J Am Heart Assoc. 2014 Jan 3;3(1):e000609. doi:</br> 10.1161/JAHA.113.000609. PubMed PMID: 24390146; PubMed Central PMCID: PMC3959688.</br>15: Goldfine AB, Buck JS, Desouza C, Fonseca V, Chen YD, Shoelson SE, Jablonski</br> KA, Creager MA; TINSAL-FMD (Targeting Inflammation Using Salsalate in Type 2</br> Diabetes–Flow-Mediated Dilation) Ancillary Study Team. Targeting inflammation</br> using salsalate in patients with type 2 diabetes: effects on flow-mediated</br> dilation (TINSAL-FMD). Diabetes Care. 2013 Dec;36(12):4132-9. doi:</br> 10.2337/dc13-0859. Epub 2013 Oct 15. PubMed PMID: 24130358; PubMed Central PMCID:</br> PMC3836144.</br>16: Jung TW, Youn BS, Choi HY, Lee SY, Hong HC, Yang SJ, Yoo HJ, Kim BH, Baik SH,</br> Choi KM. Salsalate and adiponectin ameliorate hepatic steatosis by inhibition of </br> the hepatokine fetuin-A. Biochem Pharmacol. 2013 Oct 1;86(7):960-9. doi:</br> 10.1016/j.bcp.2013.07.034. Epub 2013 Aug 13. PubMed PMID: 23948064.</br>17: Faghihimani E, Aminorroaya A, Rezvanian H, Adibi P, Ismail-Beigi F, Amini M. </br> Salsalate improves glycemic control in patients with newly diagnosed type 2</br> diabetes. Acta Diabetol. 2013 Aug;50(4):537-43. doi: 10.1007/s00592-011-0329-2.</br> Epub 2011 Sep 22. PubMed PMID: 21938543.</br>18: Summaries for patients. Salsalate for type 2 diabetes mellitus. Ann Intern</br> Med. 2013 Jul 2;159(1):I-32. doi: 10.7326/0003-4819-159-1-201307020-00001. PubMed</br> PMID: 23817718.</br>19: Goldfine AB, Fonseca V, Jablonski KA, Chen YD, Tipton L, Staten MA, Shoelson </br> SE; Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team.</br> Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann </br> Intern Med. 2013 Jul 2;159(1):1-12. doi: 10.7326/0003-4819-159-1-201307020-00003.</br> PubMed PMID: 23817699; PubMed Central PMCID: PMC4128629.</br>20: Jung TW, Choi HY, Lee SY, Hong HC, Yang SJ, Yoo HJ, Youn BS, Baik SH, Choi</br> KM. Salsalate and Adiponectin Improve Palmitate-Induced Insulin Resistance via</br> Inhibition of Selenoprotein P through the AMPK-FOXO1α Pathway. PLoS One. 2013 Jun</br> 18;8(6):e66529. Print 2013. PubMed PMID: 23825542; PubMed Central PMCID:</br> PMC3689003.</br></br> |